NCT02429973View on ClinicalTrials.gov

Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

April 30, 2015

Conditions
Osteosarcoma
Interventions
DRUG

Gemcitabine plus rapamycin

Gemcitabine and rapamycin given in combination

All Listed Sponsors
lead

Broto, Javier Martín, M.D.

INDIV

NCT02429973 - Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma | Biotech Hunter | Biotech Hunter